Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This may help. Load now
October 5, 2020 Press Release
WASHINGTON, DC – Today, U.S. Rep. Earl Blumenauer (D-OR), founder and co-chair of the Congressional Cannabis Caucus, called upon the U.S. Supreme Court to review and proceed with hearing Washington v. Barr, the most significant and potentially consequential cannabis-related lawsuit ever to be filed.
https://blumenauer.house.gov/media-center/press-releases/blumenauer-calls-supreme-court-review-historic-appeal-challenging
https://blumenauer.house.gov/media-center/press-releases/blumenauer-calls-supreme-court-review-historic-appeal-challenging
October 5, 2020 Press Release
WASHINGTON, DC – Today, U.S. Rep. Earl Blumenauer (D-OR), founder and co-chair of the Congressional Cannabis Caucus, called upon the U.S. Supreme Court to review and proceed with hearing Washington v. Barr, the most significant and potentially consequential cannabis-related lawsuit ever to be filed.
.05 that is
Good loading point. It’s been to .50 few months ago.
What’s driving this back down? They’re current. Need earnings.
Cantor Fitzgerald analyst Pablo Zuanic raised the firm's price target on Aphria (APHA) to C$15.50 from C$12.50 and keeps an Overweight rating on the shares.3 hours ago
https://thefly.com/landingPageNews.php?id=3169856&headline=APHA-Aphria-price-target-raised-to-C-from-C-at-Cantor-Fitzgerald
“Why would they build a structure that is 4 to 5 times bigger than they apparently need..”
“Cancer is a leading cause of death worldwide; due to the lack of ideal cancer biomarkers for early detection or diagnosis, most patients present with late-stage disease at the time of diagnosis, thus limiting the potential for successful treatment. Traditional cancer treatments, including surgery, chemotherapy and radiation therapy, have demonstrated very limited efficacy for patients with late-stage disease. Therefore, innovative and effective cancer treatments are urgently needed for cancer patients with late-stage and refractory disease. Cancer immunotherapy, particularly adoptive cell transfer, has shown great promise in the treatment of patients with late-stage disease, including those who are refractory to standard therapies. In this review, we will highlight recent advances and discuss future directions in adoptive cell transfer based cancer immunotherapy.”
OMID is current
Operating Results for the Three Months Ended June 30, 2020
Revenue was $463,270, increasing by 2084.4% Q/Q and 116.9% compared to the same period last year.
Gross Profit was $201,757, compared to $56,549 for the same period last year, a 256.8% improvement.
Net income was $109,311, compared to $18,228 for the same period last year, a 599.7% improvement.
“I am thrilled with the exceptional execution of my entire team during the second quarter - continuing into the third quarter - as we overcame many challenges related to the coronavirus. stated Adam Frank, OMIDs chairman and CEO. Our organizations commitment to safety, quality, integrity, and value combined with consistent innovation and operational flexibility is steadily generating exciting opportunities. In recognition of our current reporting status, I look forward to providing more detailed and consistent updates for our shareholders.”
Phantom speaks!
Remember: Went to .06 in June with peac acquisition!
Adding..
So is OMID positioned well to supply and compete for these FDA dietary or other industry manufacturers? (beyond current vape Gummie etc)
I’ve been using CBD as an aging cyclist for a year now and this is a game changing miracle cure for so many ailments. It’s going to be in EVERYTHING once regulated.
Benchman: I accumulated too. Missed market run up for this. Let’s go!
Ran to .60 in the Peac labs acquisition
And...all this cbd stuffs about to get regulated so it can be put in everything. President knows how to navigate FDA channels from Previous job. OMID IS FDA REGISTERED AND READY! https://www.navytimes.com/off-duty/military-culture/2020/09/09/navy-ramps-up-its-regulation-of-cbd-products/
1.2mm vol! 20% run. Up to .50 again?!
OMID IS FDA REGISTERED AND READY! https://www.navytimes.com/off-duty/military-culture/2020/09/09/navy-ramps-up-its-regulation-of-cbd-products/
Good news ...
I’m a little heavy so just offered 90,000 at .0105
Atty letter out!
Ran up to .50 a couple months ago
Have owned this for years. Any news?
They are doubling stores in Ontario, that will be great for Aphria
Back to .50 again! Finally...
It’s out!
Disclosure Statement Pursuant to the Pink Basic Disclosure Guidelines
a Florida Corporation
1130 Springtown Road, Suite B
Phillipsburg, NJ 08865
info@omidholdingsinc.com www.omidholdingsinc.com
SIC CODE: 3629
Quarterly Report
For the Period Ending: June 30, 2020
(the “Reporting Period”)
As of June 30, 2020, the number of shares outstanding of our Common Stock.....
??Aphria:
Preliminary results of the pediatric refractory #epilepsy clinical study led by @HospGarrahan in #Argentina report a medium decrease of 66% in the frequency of seizures. Find the report published by @SeizureJournal. bit.ly/2zHsIBC. $APHA #research #Neurology
https://twitter.com/aphrialatam/status/1299442646772068352?s=21
Phantom...
26 February 2020 Letter from the Chairman & CEO
Dear Valued Shareholder:
Letter from the Chairman & CEO
26 February 2020
Today, I would like to welcome you to our new company and provide an update on our business. The recent name and ticker symbol change - from AV1 Group, Inc. (AVOP) to OMID Holdings, Inc. (OMID) - is more than just a brand or marketing shift. It truly represents the birth of a new publicly traded company. With this letter, my intent is to shed light on the journey so far and road ahead.
Our History
OMID Holdings, Inc. has been in the CBD business for over 4 years. With a focus on cannabidiol (CBD) derived from hemp, we established our mission: to make high-quality, high-value products that consumers enjoy while truly experiencing beneficial effects. We initially achieved this with our bottled CBD vape products under our Shangri-La brand.
In the spring of 2018, we built a clean room and began manufacturing our products internally, leveraging my experience as a quality engineer in the medical device manufacturing industry. By manufacturing internally, we obtained greater control over our supply chain while improving our profit margins. It also enabled us to offer private label manufacturing services. We were the first brand to manufacture and launch CBD vape pods in the summer of 2018. We obtained distribution channels across the United States with our Shangri-La CBD vape pods and vape pen devices. In late-2018, we moved to a new, larger facility complete with a larger clean room.
The current facility is both FDA-registered and Food Grade Certified. We stand prepared to apply for additional certifications and licenses as we continue to invest in our future. In 2019, we developed and introduced our other primary in-house brand: Naturally Peaked Health Co. Our goal with Naturally Peaked was to target first-time CBD users who would respond well to our slogan: “Live Your Best Life, At Your Peak”. We have received positive customer feedback for our products and achieved grass-roots success with both of our in-house brands.
Building on a Strong Foundation
Our operational strength has been bolstered through the following achievements:
? We have demonstrated a strong use of limited capital resources
? We have invested in building strong customer relationships
? We have a professional and experienced management team
? We are flexible with low operational overhead costs
OMID Holdings, Inc. | a Publically Traded Company (OTC PINK:OMID) 1
26 February 2020 Letter from the Chairman & CEO
Our Business Model
Our services are scalable, easy to implement, attractive to industry leaders, and provide tremendous value for the end customer. During the past year, in spite of a difficult regulatory environment with respect to the vape industry, we have successfully developed multiple new distribution channels for our products. We are looking forward to leveraging our sales channels through the expansion of our product lines. As the brands we manufacture continue to grow, they will present new revenue opportunities over the coming months and years.
Our Revenue
Some of the most valuable benefits of the reverse merger include an expanded network of professionals, additional exposure for our brands and services, as well as a stronger financial position. We are in the process of completing an audit of our financials and are eager to share the results. In the meantime, I am happy to report that our unaudited 2019 revenues exceeded $500K – with YOY growth exceeding 40%. We are confident that 2020 will be a strong year for OMID Holdings, Inc. In the months to come, we will share news about new projects & contracts.
Our Key Initiatives
1. Increase Marketing Activities
We intend to establish a solid presence and reputation in the public markets which will increase awareness of the OMID Manufacturing brand. With most of our current private label customers initially obtained through word of mouth, we expect improved communication to yield a variety of benefits. Effective marketing will not solely increase revenues but it will represent additional value to our customers through broader exposure of our in-house and private label brands. Marketing efforts will focus on building our brand via social media, interviews, trade shows, and frequent updates for our shareholders as we make progress toward achieving our goals.
2. Expand Current Sales Channels
The maximum potential revenue from our current sales channels are yet to be realized. Therefore, we will revitalize and expand our product lines with higher quality and better value products. In addition, we hope to innovate and market novel products that the general cannabis industry has yet to discover and/or recognize. We will gradually improve our facility in order to meet government regulatory requirements and growing customer compliance demands.
Conclusion
Today, with our growth as a health and wellness company, we are continuing to increase our footprint through networking and marketing efforts in the aggressively growing and rapidly evolving cannabis industry. We believe that our experience and expertise, paired with our efficient, cost-effective operation has positioned OMID Holdings, Inc. for success.
We expect to achieve operational resilience through regulatory preparedness and by capitalizing on new opportunities. We do not compromise with our commitment to product safety, quality, integrity, and overall value which sets us apart from much of our competition.
OMID Holdings, Inc. | a Publically Traded Company (OTC PINK:OMID) 2
26 February 2020 Letter from the Chairman & CEO
With continued innovation and hard work, my team and I look forward to earning the support and trust of our shareholders. I would like to publicly state that I consider our shareholders as an extension of our team and will strive to build a friendly shareholder relationship through regular communication and updates.
Over the next few months, we are going to be focusing on continuing to acquire new private label customers while introducing new brands and products to the market. In the meantime, please review our various websites and social media accounts. Should you have any questions, comments, concerns or ideas: please do not hesitate to contact us via email at info@omidholdingsinc.com.
Respectfully,
Adam Frank Chairman & CEO OMID Holdings, Inc.
Safe Harbor Act:
Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
OMID Holdings, Inc. | a Publically Traded Company (OTC PINK:OMID) 3
Pre trade ask 2.39
“We have completed the construction of our facility in Germany and we are currently in the process of moving our machinery in. Once fully operational it is going to be one of the most advanced indoor growing facilities worldwide”
We have completed the construction of our facility in Germany and we are currently in the process of moving our machinery in. Once fully operational it is going to be one of the most advanced indoor growing facilities worldwide. $APHA pic.twitter.com/nkWVHC4gNF
— Irwin D. Simon (@IrwinDSimon) August 6, 2020
Cannibidiol showed good effectiveness, with a ≥ 50 % reduction in seizure frequency in 73.5 % of the patients.
https://www.seizure-journal.com/article/S1059-1311(20)30167-9/fulltext
Cannibidiol showed good effectiveness, with a ≥ 50 % reduction in seizure frequency in 73.5 % of the patients.
https://www.seizure-journal.com/article/S1059-1311(20)30167-9/fulltext
Why is it treading water?
“In terms of core business expectations for the quarter, Aphria largely delivered as promised. While it perhaps wasn’t the exclamation point investors were hoping for, the company nailed many of the important metrics that mattered.”
-in their opinion IMO
https://thedalesreport.com/cannabis/aphria-sells-off-as-asset-impairment-atm-program-weigh-on-stock/
@sirwilliambrooke
“In every interview today Irwin touched on the need for consolidation. Is he manipulating the media reaction to his upcoming $ACB deal? I think so! He would not state this unless something was up, it’s not a bullish statement unless u are consolidating. “
In his opinion. IMO
https://twitter.com/gopdemocrat/status/1288649936779669504?s=21